Takeda Chemical Industries, Inc.

Takeda Pharmaceutical Company Limited

Takahito Kitayoshi

Mitsuru Shiraishi

Tsuneo Oda

Yoshio Aramaki

Susumu Honda

Masaomi Miyamoto

Mami Ojima

Hisao Kasuga

Masami Isaka

Kazuaki Ikeya

There is provided an agent for preventing the recurrence of cerebrovascular disorder and an agent for ameliorating troubles following cerebrovascular disorder and inhibiting the progress thereof which contain a compound having an angiotensin II antagonistic activity, a prodrug thereof or a salts thereof.

Preventives for the recurrence of cerebrovascular failure and agents for ameliorating troubles following cerebrovascular failure and inhibiting progress thereof

TNF-&agr; inhibitors containing a heterocyclic compound having angiotensin II antagonistic activity which are useful as preventives/remedies for inflammatory diseases, etc.

TNF-&agr; inhibitors

Anilide derivative, production and use thereof

This invention is to provide a compound of the formula: ##STR1## wherein R.sup.1 is an optionally substituted 5- to 6-membered ring: C is a divalent group of the formula: ##STR2## wherein the ring A is an optionally substituted 5- to 6-membered aromatic ring, X is an optionally substituted C, N or O atom, and the ring B is an optionally substituted 5- to 7-membered ring; Z is a chemical bond or a divalent group; R.sup.2 is (1) an optionally substituted amino group in which a nitrogen atom may form a quaternary ammonium, etc., or a salt thereof, which is useful for antagonizing MCP-1 receptor.

Provided is a non-human animal in which an exogeneous gene, a mutant gene thereof of a monocyte chemoattractant protein and/or a receptor thereof is introduced. The present transgenic animals can be utilized as a pathologic model animal for heart diseases, respiratory diseases, joint diseases, kidney diseases, arteriosclerosis, psoriasis, hyperlipidemia, allergic diseases, bone diseases, blood diseases, cerebrovascular disorders, traumatic cerebral disorders, infections diseases, demantia or chroric inflammatory diseases etc. Thus, it is possible to elucidate the mechanism of pathogenesis of these diseases, to determine therapies, and to screen for candidate compounds for the purpose of research and development of therapeutic drugs.

Monocyte chemoattractant protein and its receptor transgenic animal

Growing community of inventors

Suita, Japan

Takahito Kitayoshi